Today the FDA announced the approval of inclisiran (Leqvio) as a treatment for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional low-density [...]
The Food and Drug Administration (FDA) approved today a new drug to treat adult and pediatric patients aged 12 years and older with Homozygous Familial Hypercholesterolemia (HoFH), the rare and [...]
the Family Heart Foundation started 2021 off with an impactful Listening Session with the Food and Drug Administration (FDA) Center for Drug Evaluation and Research Division of Diabetes, Lipid Disorders, and Obesity [...]
Copyright © - 2025 All Rights Reserved Family Heart Foundation
Early diagnosis and treatment can mean years, even decades of life for someone with impacted by familial hypercholesterolemia (FH) and lipoprotein(a), also known as Lp(a).
Yet a majority of people with these inherited disorders haven’t even been diagnosed.
Your gift allows us to continue to engage the research, advocacy, and education that helps individuals with FH, HoFH, or elevated Lp(a) get the vital medical care that they need.
